GlycoNex Inc. is a Taiwan-based company principally engaged in the development and licensing of anti-cancer monoclonal antibodies, as well as the provision of carbohydrate antigen and protein drug related commission services. The Company is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The Company distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/26/30	NT$21.30	-0.70%	1,42,273
29/26/29	NT$21.45	-0.23%	48,703
28/26/28	NT$21.50	0.00%	62,366
27/26/27	NT$21.50	+0.23%	86,428
22/26/22	NT$21.45	-1.38%	73,146

End-of-day quote Taipei Exchange

More quotes

End-of-day quote Taipei Exchange 30/10/2026			5-day change	1st Jan Change
21.30 ^TWD	-0.70%		-0.70%	-17.28%

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI

Market Cap	239.67Cr 7.35Cr 6.58Cr 6.05Cr 5.48Cr 10Cr 697.42Cr 10Cr 72Cr 29Cr 366.86Cr 28Cr 27Cr 1.16TCr	P/E 2024	-11.8x	P/E 2025	-11.9x
Enterprise Value	217.7Cr 6.67Cr 5.98Cr 5.5Cr 4.98Cr 9.31Cr 633.49Cr 9.48Cr 66Cr 26Cr 333.23Cr 25Cr 25Cr 1.05TCr	EV / Sales 2024	154x	EV / Sales 2025	67.8x
Free-Float	79.89%	Yield 2024 *	-	Yield 2025	-

13/08	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
03/08	GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021	CI
11/06	Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8	CI
14/05	GlycoNex Incorporation Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
15/04	GlycoNex, Inc Receives PMDA Approval To Initiate First-In-Human Phase 1 Trial Of GNX1021 In Gastrointestinal Cancers	CI
23/03	GlycoNex Inc. And Nippon Kayaku Co., Ltd. Enters Collaboration To Advance Next-Generation ADC Candidate	CI
14/03	GlycoNex Incorporation Reports Earnings Results for the Full Year Ended December 31, 2025	CI
08/12	GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program	CI
24/11	Glyconex, Inc. and Hokkaido University Hospital Launch Study to Advance Glycan-Directed ADC Development in Gastric Cancer	CI
14/11	GlycoNex Incorporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
29/25/29	GlycoNex announces last patient dosed in phase 3 trial of SPD8, a denosumab biosimilar for osteoporosis	RE
29/25/29	GlycoNex, Inc. Announces Last Patient Dosed in Phase 3 Trial of SPD8, a Denosumab Biosimilar for Osteoporosis	CI
13/25/13	GlycoNex Incorporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

1 day	-0.70%
1 week	-0.70%
Current month	-4.70%
1 month	-1.84%
3 months	-3.40%
6 months	-9.36%
Current year	-17.28%

GlycoNex Incorporation Share Price

Stocks

4168

TW0004168000

Biotechnology & Medical Research

Valuation: GlycoNex Incorporation

Chart: GlycoNex Incorporation

Latest news: GlycoNex Incorporation

Press Releases: GlycoNex Incorporation

Quotes and Performance

Price Extremes

Managers and Directors: GlycoNex Incorporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 week	20.9	22.05
1 month	20.9	23.55
Current year	20.9	30
1 year	20.55	30
3 years	15.6	31.85
5 years	15.6	46.9
10 years	10.2	46.9

Manager	Title	Age	Since
Mei Chun Yang CEO	Chief Executive Officer	-	01/01/2019
Dih Fen Wu DFI	Director of Finance/CFO	-	01/01/2010
Yao Hua Lue IRC	Investor Relations Contact	-	12/11/2012

Director	Title	Age	Since
Kao Chung Tsai BRD	Director/Board Member	64	-
Tong Hsuan Chang CHM	Chairman	-	01/02/2001
Ling-Chun Tsai BRD	Director/Board Member	-	25/05/2012

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLYCONEX INCORPORATION	-0.70%	-0.70%	-6.78%	-26.93%	7.41Cr
WUXI APPTEC CO., LTD.	-0.62%	+0.50%	+33.92%	+60.07%	6.44TCr
ARGENX SE	+0.35%	+3.04%	+12.64%	+83.62%	5.62TCr
LONZA GROUP AG	+0.53%	+2.55%	+13.90%	+104.77%	5.42TCr
IQVIA HOLDINGS INC.	-2.81%	-3.95%	+22.72%	+48.57%	4.53TCr
BEONE MEDICINES AG	-0.33%	-3.12%	+17.62%	+117.27%	4.22TCr
REVOLUTION MEDICINES, INC.	+0.55%	+1.93%	+229.73%	+928.00%	4.08TCr
GENMAB A/S	+3.27%	+47.40%	+110.44%	+94.92%	3.38TCr
CELLTRION, INC.	+1.22%	-1.39%	+13.92%	+46.95%	3.22TCr
WUXI BIOLOGICS (CAYMAN) INC.	-1.29%	-1.72%	+21.00%	-6.85%	2.36TCr
Average	+0.01%	+4.18%	+46.91%	+145.04%	3.93TCr
Weighted average by Cap.	+0.01%	+3.64%	+49.56%	+162.44%

	2024	2025
Net sales	1.47Cr 5L 4L 4L 3L 6L 4.28Cr 6L 44.26L 17.77L 2.25Cr 16.91L 16.55L 7.1Cr	3.79Cr 11.6L 10.39L 10L 9L 16.19L 11Cr 16.49L 1.14Cr 45.76L 5.8Cr 43.55L 42.62L 18Cr
Net income	-23Cr -70.4L -63.05L -57.99L -52.55L -98.22L -67Cr -1Cr -6.92Cr -2.78Cr -35Cr -2.64Cr -2.59Cr -110.88Cr	-24Cr -72.09L -64.56L -59.39L -53.81L -1.01Cr -68Cr -1.02Cr -7.08Cr -2.84Cr -36Cr -2.71Cr -2.65Cr -113.55Cr
Net Debt	-44Cr -1.35Cr -1.21Cr -1.12Cr -1.01Cr -1.89Cr -128.65Cr -1.93Cr -13Cr -5.34Cr -68Cr -5.08Cr -4.98Cr -213.42Cr	-22Cr -67.33L -60.3L -55.47L -50.26L -93.95L -64Cr -95.7L -6.61Cr -2.66Cr -34Cr -2.53Cr -2.47Cr -106.06Cr